I
mmune disturbances play manifold roles in the pathogenesis of ischemic stroke. Regulatory mechanisms that continuously fine-tune the immune system are, therefore, essential for protection and recovery from stroke. Regulatory T cells (Tregs) is suggested to exert neuroprotection by Liesz et al 1 on the basis of their findings that Tregs depletion with CD25 antibody exacerbates brain damage and worsens functional deficits 7 days after transient ischemic stroke. The endogenous Treg-afforded protection is late in onset, as Treg depletion failed to influence brain damage ≤4 days post ischemia. [1] [2] [3] This late action is consistent with delayed Treg infiltration into the brain until 3 to 5 days after middle cerebral artery occlusion. 1 Interestingly, anti-inflammatory effects of Tregs were observed before their appearance in the brain, suggesting early peripheral protective mechanisms of Tregs.
1 Such anti-inflammatory effects, however, are not potent enough to reduce early brain damage, probably because of insufficient Treg numbers in the circulation. In support, clinical studies report that the number of circulating Tregs decreases transiently, but dramatically in the first 2 days after stroke. 4 Therefore, adoptive transfer of Tregs soon after stroke may provide a novel immunotherapeutic strategy for stroke.
Surprisingly, Kleinschnitz et al 5 recently demonstrated an opposite role for Tregs to exacerbated brain injury early after transient ischemia. The animal model they used was different from Liesz study in several aspects, including the duration of ischemia and methods for Treg depletion, which possibly contribute to the discrepancies between these 2 studies. 5 For example, instead of using CD25 antibody for Treg depletion, Kleinschnitz used a DEREG transgenic mouse in which Foxp3+ cells are inducibly ablated. Neither CD25 nor Foxp3 is exclusively expressed on Tregs. 6 Therefore, these 2 depletion protocols may differentially target a small portion of non-Tregs population and confound the data interpretation. Notably, another group using the DEREG mouse showed that Treg depletion has no effect on the ischemic brain 4 days after injury, 3 which is against the Kleinschnitz study and tips the balance in favor of the Liesz study. Unfortunately, late stage effect of Tregs depletion was not addressed in this study. Apparently, more investigations are necessary to confirm the function of endogenous Tregs in ischemic stroke.
Given the potential protective effect of endogenous Tregs in the ischemic brain 1 and the known therapeutic effects of Treg transplantation in ischemia/reperfusion models in many other organs, we explored the effect of Treg adoptive therapy in models of focal cerebral ischemia/reperfusion, in adherence with Stroke Therapy Academic Industry Roundtable (STAIR) recommendations. Studies conducted by 2 independent laboratories on 2 different species demonstrated that postischemic delivery of Tregs markedly reduced brain infarct size and improved neurological functions out to 4 weeks. 2 Notably, the therapeutic time window of Tregs lasted 24 hours after the onset of ischemia, making it more applicable to humans who may not be treated in the clinic for many hours from symptom onset.
In contrast with the relatively late action of endogenous Tregs, transplanted Tregs led to an early attenuation of bloodbrain barrier disruption and reduced infiltration of inflammatory cells into the lesioned brain. These effects result in an early reduction of infarct size at 3 days post ischemia. The distinct effects of transferred and endogenous Tregs on early stage ischemic brain injury may reflect that the therapeutic concentration of exogenous Tregs (2×10 6 /mouse) greatly outnumbers endogenous circulating Tregs. In our hands, transplanted Tregs at a concentration <1×10 6 cells/mouse failed to offer any early protection. However, Kleinschnitz used even lower concentrations of Tregs (7.5×10 5 /mouse) and observed exacerbation of ischemic damage. 5 One possible interpretation of the discrepancies between our data and data of Kleinschnitz 5 is that Tregs delivered before or after stroke exert opposing functions. Our protocol involved postischemic Treg delivery, whereas Kleinschnitz administered Tregs 24 hours before ischemic challenge. It may be counterproductive to increase Tregs in the immediate preischemic period as the immune milieu before stroke may not be permissive for proper Treg action. However, a previous study contradicted this notion as priming Tregs in vivo by repetitive intranasal administration of recombinant E-selectin 10 days before ischemia reduced brain infarct volume and improved functional performance after permanent middle cerebral artery occlusion. 7 The latter findings suggest that induction of Tregs long before stroke may also be protective. Therefore, the timing of Treg delivery seems to be critical for
PRO: Regulatory T Cells Are Protective in Ischemic Stroke
Xiaoming Hu, MD, PhD; Peiying Li, MD, PhD; Jun Chen, MD Xiaoming Hu, Peiying Li and Jun Chen
